Terlipressin effect on hepatorenal syndrome: Updated meta‐analysis of randomized controlled trials
Abstract Background and Aim Hepatorenal syndrome (HRS) is a fatal complication of liver cirrhosis with a limited pharmacological option. Terlipressin is a vasoconstrictor that is approved in many countries but not yet in the United States. This is a meta‐analysis of randomized controlled trials (RCT...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-08-01
|
Series: | JGH Open |
Subjects: | |
Online Access: | https://doi.org/10.1002/jgh3.12600 |